Angewandte
Chemie
DOI: 10.1002/anie.201206283
Platinum Chemistry
Two-Photon-Activated Ligand Exchange in Platinum(II) Complexes**
Yao Zhao, Gareth M. Roberts, Simon E. Greenough, Nicola J. Farrer, Martin J. Paterson,
William H. Powell, Vasilios G. Stavros,* and Peter J. Sadler*
Two-photon absorption (TPA) was theoretically proposed in
1931;[1] (near-)simultaneous absorption of two photons
(approximately 10À16 s) by an atom or molecule can drive
a transition equivalent to the absorption of a single photon of
twice the energy,[2] ultimately activating the same photo-
physical or photochemical processes induced by one-photon
absorption (OPA).[2,3] However, TPA probabilities are typi-
cally extremely small, and the first experimental evidence of
TPA was not obtained until the 1960s, using a ruby laser.[4]
Now femtosecond (fs) laser systems, which generate very high
instantaneous photon densities, have opened up a plethora of
multiphoton applications,[5] such as fluorescence microscopy[6]
and photodynamic therapy (PDT).[7]
nyl)ethynyl]pyridine (MOPEP) since we believed it would
have potential for TPA. Reported work has shown that large
TPA cross-sections (d) are often associated with long, co-
planar p-conjugated chains with opposing terminal donor and
acceptor (D-A) moieties.[2,11] Complex 1 was synthesized as
shown in Scheme 1. The cis geometry of the product was
determined by 195Pt NMR spectroscopy (see Supporting
Information).
Herein, we report the first TPA-induced ligand substitu-
tion on a square-planar PtII complex. We compare OPA with
TPA, and we use linear and quadratic density functional
response theory to identify the electronic transitions involved
and rationalize the wavelength dependence of the TPA. There
has been broad interest in controlling the reactivity of PtII
centers because of the clinical use of PtII drugs for the
treatment of cancer. Platinum anticancer prodrugs such as
PtIV diazidodihydroxido complexes[8] and PtIV dichloridodi-
hydroxido or tetrachlorido complexes[9] are effective with
OPA using UVA, or blue light, and are thus more suitable for
surface tumors, whereas deeper tissue penetration requires
longer wavelengths (620–850 nm).[10]
Scheme 1. Synthesis of the complex cis-[PtCl2(MOPEP)2] (1).
The absorption spectra of 1 and MOPEP in acetonitrile
(MeCN) are shown in the Supporting Information, Figure S3.
MOPEP has two major absorption bands centered at l =
297 nm and 310 nm, which are both assigned to intra-
molecular charge-transfer (CT) transitions. The absorption
centered at 344 nm for 1 can be assigned to a number of
metal-to-ligand charge-transfer (MLCT) transitions; see
Supporting Information for further details. In MeCN, 1 has
no absorbance greater than 500 nm and is stable in the dark
and upon irradiation with light l > 500 nm. 1 was also stable in
MeCN when heated to 343–353 K (MeCN b.p. = 355 K). The
melting of 1 was investigated and decomposition was
observed only above 473 K.
The photodecomposition of 1 in MeCN following OPA
was studied by UV/Vis absorption spectroscopy. Upon
irradiation of 1 with UVA (l = 330–380 nm, Figure 1a) or
broadband white light (l = 400–700 nm, Figure 1b), the
intensity of the major absorption band for 1 (at 344 nm)
decreased. After irradiation with UVA for five minutes
(Figure 1a, green curve) or white light for 30 minutes (Fig-
ure 1b, magenta curve), the absorbance at 344 nm disap-
peared, indicating complete photodecomposition of 1. Con-
comitantly, two strong absorption bands at approximately
300 nm emerged in the spectra; these display the same
spectral profile as the MOPEP ligand (Figure S3). This
suggests that photodecomposition of 1 proceeds by substitu-
tion of the MOPEP ligands with solvent MeCN molecules
(Scheme 2). After only one minute of irradiation with UVA,
no recovery of 1 was observed (after 12 hours in the dark), as
determined by UV/Vis spectroscopy. Notably, the rate of
photodecomposition upon irradiation with UVA was much
faster than with the broadband white light despite the lower
power density of the UVA source. This is in agreement with
We designed the novel PtII complex, cis-[PtCl2(MOPEP)2]
(1) containing the p-conjugated ligand 4-[2-(4-methoxyphe-
[*] Dr. Y. Zhao, Dr. G. M. Roberts,[+] S. E. Greenough,[+] Dr. N. J. Farrer,
W. H. Powell, Prof. Dr. V. G. Stavros, Prof. Dr. P. J. Sadler
Department of Chemistry, University of Warwick
Coventry, CV4 7AL (UK)
E-mail: v.stavros@warwick.ac.uk
Dr. M. J. Paterson
Institute of Chemical Sciences, Heriot-Watt University
Edinburgh, EH14 4AS (UK)
[+] These authors contributed equally to this work.
[**] Y.Z. thanks the University of Warwick and ORSAS for PhD funding.
G.M.R. thanks the Leverhulme Trust for postdoctoral funding.
S.E.G. thanks the EPSRC for a doctoral training studentship. M.J.P.
thanks the European Research Council for funding under the
European Union’s Seventh Framework Programme (FP7/2007-
2013)/ERC Grant No. 258990. V.G.S. thanks the EPSRC for equip-
ment grants (EP/E011187 and EP/H003401), the Royal Society for
a University Research Fellowship and the University of Warwick for
an RDF Award. N.J.F. and P.J.S. thank the EPSRC (EP/G006792/1)
and the ERC (award no. 247450).
Supporting information for this article (experimental details) is
Angew. Chem. Int. Ed. 2012, 51, 11263 –11266
ꢀ 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
11263